Regeneron Pharmaceuticals Inc - Asset Resilience Ratio
Regeneron Pharmaceuticals Inc (REGN) has an Asset Resilience Ratio of 13.27% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Regeneron Pharmaceuticals Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Regeneron Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Regeneron Pharmaceuticals Inc.
Liquid Assets Composition Over Time
This chart breaks down Regeneron Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of Regeneron Pharmaceuticals Inc to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $5.54 Billion | 13.27% |
| Total Liquid Assets | $5.54 Billion | 13.27% |
Asset Resilience Insights
- Moderate Liquidity: Regeneron Pharmaceuticals Inc has 13.27% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Regeneron Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Regeneron Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Regeneron Pharmaceuticals Inc (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Regeneron Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 13.53% | $5.49 Billion | $40.56 Billion | -3.75pp |
| 2024-12-31 | 17.28% | $6.52 Billion | $37.76 Billion | -7.25pp |
| 2023-12-31 | 24.53% | $8.11 Billion | $33.08 Billion | +8.66pp |
| 2022-12-31 | 15.87% | $4.64 Billion | $29.21 Billion | +4.83pp |
| 2021-12-31 | 11.04% | $2.81 Billion | $25.43 Billion | +2.93pp |
| 2020-12-31 | 8.12% | $1.39 Billion | $17.16 Billion | -2.67pp |
| 2019-12-31 | 10.78% | $1.60 Billion | $14.81 Billion | -0.65pp |
| 2018-12-31 | 11.44% | $1.34 Billion | $11.73 Billion | +4.63pp |
| 2017-12-31 | 6.81% | $596.85 Million | $8.76 Billion | -0.41pp |
| 2016-12-31 | 7.22% | $503.48 Million | $6.97 Billion | +3.01pp |
| 2015-12-31 | 4.21% | $236.12 Million | $5.61 Billion | -2.29pp |
| 2014-12-31 | 6.50% | $251.76 Million | $3.87 Billion | +1.14pp |
| 2013-12-31 | 5.37% | $158.38 Million | $2.95 Billion | +1.63pp |
| 2012-12-31 | 3.74% | $77.82 Million | $2.08 Billion | +0.47pp |
| 2011-12-31 | 3.27% | $43.33 Million | $1.32 Billion | -9.28pp |
| 2010-12-31 | 12.56% | $136.80 Million | $1.09 Billion | -5.56pp |
| 2009-12-31 | 18.11% | $134.25 Million | $741.20 Million | -15.76pp |
| 2008-12-31 | 33.87% | $226.95 Million | $670.04 Million | +5.30pp |
| 2007-12-31 | 28.57% | $267.53 Million | $936.26 Million | -9.27pp |
| 2006-12-31 | 37.84% | $221.40 Million | $585.09 Million | +10.91pp |
| 2005-12-31 | 26.93% | $114.04 Million | $423.50 Million | -14.24pp |
| 2004-12-31 | 41.16% | $194.75 Million | $473.11 Million | +4.57pp |
| 2003-12-31 | 36.59% | $175.49 Million | $479.56 Million | -10.45pp |
| 2002-12-31 | 47.04% | $184.19 Million | $391.57 Million | +19.25pp |
| 2001-12-31 | 27.79% | $137.69 Million | $495.40 Million | -13.80pp |
| 2000-12-31 | 41.60% | $86.63 Million | $208.27 Million | +10.57pp |
| 1999-12-31 | 31.02% | $42.50 Million | $137.00 Million | -- |
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degenera… Read more